849 related articles for article (PubMed ID: 29869756)
1. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
Yamamoto S
Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
[TBL] [Abstract][Full Text] [Related]
2. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.
Taki K; Tsuruta Y; Niwa T
Am J Nephrol; 2007; 27(1):30-5. PubMed ID: 17215572
[TBL] [Abstract][Full Text] [Related]
3. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
[TBL] [Abstract][Full Text] [Related]
4. Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis.
Takkavatakarn K; Wuttiputinun T; Phannajit J; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
J Nephrol; 2021 Dec; 34(6):1805-1817. PubMed ID: 33484425
[TBL] [Abstract][Full Text] [Related]
5. Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis.
Wakamatsu T; Yamamoto S; Yoshida S; Narita I
Toxins (Basel); 2024 May; 16(6):. PubMed ID: 38922148
[TBL] [Abstract][Full Text] [Related]
6. Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis.
Hsu HJ; Yen CH; Chen CK; Wu IW; Lee CC; Sun CY; Chang SJ; Chou CC; Hsieh MF; Chen CY; Hsu CY; Tsai CJ; Wu MS
Gen Hosp Psychiatry; 2013; 35(1):23-7. PubMed ID: 23044245
[TBL] [Abstract][Full Text] [Related]
7. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
8. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
[TBL] [Abstract][Full Text] [Related]
9. Uremic Toxins and Vascular Dysfunction.
Six I; Flissi N; Lenglet G; Louvet L; Kamel S; Gallet M; Massy ZA; Liabeuf S
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32570781
[TBL] [Abstract][Full Text] [Related]
10. β(2)-microglobulin amyloidosis.
Corlin DB; Heegaard NH
Subcell Biochem; 2012; 65():517-40. PubMed ID: 23225015
[TBL] [Abstract][Full Text] [Related]
11. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients.
Ito S; Yoshida M
Toxins (Basel); 2014 Feb; 6(2):665-78. PubMed ID: 24561478
[TBL] [Abstract][Full Text] [Related]
12. Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration.
Böhringer F; Jankowski V; Gajjala PR; Zidek W; Jankowski J
ASAIO J; 2015; 61(1):55-60. PubMed ID: 25419832
[TBL] [Abstract][Full Text] [Related]
13. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique.
Brettschneider F; Tölle M; von der Giet M; Passlick-Deetjen J; Steppan S; Peter M; Jankowski V; Krause A; Kühne S; Zidek W; Jankowski J
Artif Organs; 2013 Apr; 37(4):409-16. PubMed ID: 23330821
[TBL] [Abstract][Full Text] [Related]
14. Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling.
Nakano T; Katsuki S; Chen M; Decano JL; Halu A; Lee LH; Pestana DVS; Kum AST; Kuromoto RK; Golden WS; Boff MS; Guimaraes GC; Higashi H; Kauffman KJ; Maejima T; Suzuki T; Iwata H; Barabási AL; Aster JC; Anderson DG; Sharma A; Singh SA; Aikawa E; Aikawa M
Circulation; 2019 Jan; 139(1):78-96. PubMed ID: 30586693
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis.
Yamamoto S; Yamamoto K; Hirao Y; Yamaguchi K; Nakajima K; Sato M; Kawachi M; Domon M; Goto K; Omori K; Iino N; Shimada H; Aoyagi R; Ei I; Goto S; Goto Y; Gejyo F; Yamamoto T; Narita I
Amyloid; 2024 Jun; 31(2):105-115. PubMed ID: 38343068
[TBL] [Abstract][Full Text] [Related]
16. Uremic Toxicity and Bone in CKD.
Yamamoto S; Fukagawa M
J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
[TBL] [Abstract][Full Text] [Related]
17. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in understanding dialysis-related amyloidosis.
Yamamoto S; Kazama JJ; Narita I; Naiki H; Gejyo F
Bone; 2009 Jul; 45 Suppl 1():S39-42. PubMed ID: 19303954
[TBL] [Abstract][Full Text] [Related]
19. Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction.
Jourde-Chiche N; Dou L; Cerini C; Dignat-George F; Brunet P
Semin Dial; 2011; 24(3):327-37. PubMed ID: 21682773
[TBL] [Abstract][Full Text] [Related]
20. Uremic toxicity and sclerostin in chronic kidney disease patients.
Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
